PT-141

PT-141 (bremelanotide) is a peptide studied for sexual desire and arousal support. It acts centrally in the brain through melanocortin receptors, particularly MC3R and MC4R, rather than working mainly through blood flow. It is studied for sexual desire, arousal, pleasure, and orgasm intensity in both men and women, and can be useful where sexual issues are more central or psychological in nature.

• Sexual desire
• Arousal and pleasure intensity
• Orgasm intensity
• Female sexual-desire research
• Central or psychological sexual dysfunction

• Acts in the brain via melanocortin receptors MC3R and MC4R
• Studied for sexual desire and arousal
• May increase pleasure and orgasm intensity
• Studied where sexual dysfunction is more central or psychological
• Works independently of blood flow or hormonal status

Reconstitution

2 mL bacteriostatic water

Final concentration

5 mg/mL

Dose range, men

0.75 mg (15 units) to 1.25 mg (25 units)

Dose range, women

0.5 mg (10 units) to 1 mg (20 units)

Frequency

As needed, 1–2 times per week, with a maximum of 8 doses per month on the sheet

Administration

Subcutaneous injection

Notes

Not appropriate for daily use. The sheet notes nausea can occur, often at the right side of the abdomen, and that tolerance to nausea may build.

Research duration on the sheet: As needed, up to 8 doses per month on the source sheet.

• 10 mg + 2 mL bacteriostatic water = 5 mg/mL.
• 15 units = 0.75 mg. 25 units = 1.25 mg. 10 units = 0.5 mg. 20 units = 1 mg.

• The sheet gives a range rather than a weekly escalation.
• Men: 0.75–1.25 mg. Women: 0.5–1 mg. As needed, not daily.

• For educational and research purposes only.
• Not appropriate for daily use.
• People who are sensitive to nausea or flushing, who should avoid frequent use, or who should not use this without professional guidance are called out on the sheet.
• Not recommended during pregnancy or breastfeeding.
• Store appropriately after reconstitution.

• Nausea is the effect most clearly noted on the sheet. It may lessen with repeated use.

Human research

Published clinical literature, see references

Mechanistic evidence

Central melanocortin pathway

Completed published studies are listed below and labeled as in vitro, animal, or human research. Favorable and unfavorable results are both included, including cancer studies. This is not every paper on the compound, and it is not a recommendation or a dose.

A completed cancer study of this compound was not identified.

• Bremelanotide for hypoactive sexual desire disorder: two randomized phase 3 trialsHuman

  Premenopausal women. As-needed bremelanotide, the same molecule as PT-141, increased desire scores and reduced related distress compared with placebo. Nausea, flushing, and headache were more common.

10 mg vial. Format: Lyophilized powder.